Clinical Trials Logo

Filter by:
NCT ID: NCT05739487 Completed - Clinical trials for Central Retinal Artery Occlusion

Changes of Visual Field Defects After IAT for CRAO

Start date: July 1, 2020
Phase:
Study type: Observational

Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis. Though traditional conservative treatments are widely used, none of them is proved to be effective. A number of meta-analyses and observational studies indicate intravenous thrombolysis to be beneficial in CRAO. Selective intra-arterial thrombolysis (IAT) introducing rt-PA directly into the ophthalmic circulation by super-selective microcatheterization may reduce the complications such as intracranial and systemic hemorrhage. The residual visual field is significant for patients with CRAO who have poor central visual acuity. Thus, it is clinically significant to study the changes in visual fields in eyes with CRAO.

NCT ID: NCT05739409 Not yet recruiting - Clinical trials for Acute Myelogenous Leukemia

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Start date: February 2023
Phase: N/A
Study type: Interventional

This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.

NCT ID: NCT05739383 Recruiting - Clinical trials for Primary Prevention of Atherosclerotic Cardiovascular Disease

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Start date: March 9, 2023
Phase: Phase 3
Study type: Interventional

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.

NCT ID: NCT05739318 Completed - Clinical trials for Therapeutic Procedural Complication

the Diameter of Double-lumen Tube Measured by Different Methods

Start date: February 15, 2023
Phase: N/A
Study type: Interventional

The comparison of the diameter of double-lumen tube at the cuff of endotracheal and endobronchial during the cuff was collapse or inflated as a guide for the selection of the size of double-lumen tube.

NCT ID: NCT05739253 Recruiting - Aortic Stenosis Clinical Trials

Changes of Ascending Aortic Diameter in Patients Undergoing Transcatheter Aortic Valve Replacement

Start date: March 22, 2022
Phase:
Study type: Observational

The goal of this observational study is to assess the changes of ascending aortic diameter in patients undergoing transcatheter aortic valve replacement. The main questions it aims to answer are: 1. whether the ascending aortic diameter increases or remains stable after transcatheter aortic valve replacement, especially in patients with preoperative ascending aortic dilatation; 2. the determinants of postoperative ascending aortic dilatation.

NCT ID: NCT05739227 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

Start date: March 1, 2023
Phase: Early Phase 1
Study type: Interventional

This is an open label, single-arm, Phase I study to evaluate the efficacy and safety of allogenic CD19-CAR-NK cells in subjects with refractory or relapsed B-cell hematologic malignancies. A leukapheresis procedure will be performed to manufacture Anti-CD19 chimeric antigen receptor (CAR) modified NK cells. Prior to allogenic CD19-CAR-NK cells infusion subjects will receive lymphodepleting therapy with fludarabine, cyclophosphamide and etoposide.

NCT ID: NCT05739188 Recruiting - Clinical trials for Multiple Myeloma in Relapse

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Start date: February 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-GPRC5D CAR-T cells therapy for relapsed and refractory(r/r) multiple myeloma(MM).

NCT ID: NCT05739110 Completed - Clinical trials for Hepatocellular Carcinoma

HCC Staging Modified by Tumor Micronecrosis

Start date: July 15, 2022
Phase:
Study type: Observational

Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.

NCT ID: NCT05739045 Recruiting - Gastric Cancer Clinical Trials

Nivolumab Combined With SOX Used in the Perioperative Treatment

Start date: November 3, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;

NCT ID: NCT05739019 Recruiting - COVID-19 Clinical Trials

The Impact of Past Coronavirus Disease 19 (COVID-19) Infection on the Live Birth Rates of Frozen Embryo Transfer Cycles

Start date: February 23, 2023
Phase:
Study type: Observational

This is a prospective observational study. In this study, we aim to investigate the effect of a recent past Covid-19 infection on the live birth rate in the frozen embryo transfer cycles